Sunday, 04 December 2022


ArchiMed invests in PlasmidFactory, a German gene and cell therapy specialist

28 September 2022 | News

PlasmidFactory is the second investment of ArchiMed’s MED Platform II, which began fundraising in January

Trans-Atlantic private equity healthcare specialist ArchiMed has invested in Bielefeld, Germany-based PlasmidFactory. Founded in 2000, PlasmidFactory is the leading contract manufacturer and service provider for plasmid and minicircle DNA.

PlasmidFactory develops and manufactures exceptionally high-grade plasmids and minicircles, used to modify cells and produce viral gene therapy vectors like AAV, LV and mRNA for combating everything from viruses like COVID-19 to seemingly intractable diseases like cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDs (including CAR-T cell applications). Plasmids are notably a key component for the production of mRNA COVID-19 vaccines.

PlasmidFactory is the second buy-and-build investment of ArchiMed’s MED Platform II fund, which began fundraising in January. The fund currently exceeds in size its predecessor fund, the fully-invested, €1.5 billion MED Platform I fund. A final target size for MED Platform II has not been disclosed.

PlasmidFactory has seen its revenues grow an average of 100 percent annually since 2019. The company opened a new HQ (High Quality) production facility in May, 2022 that generates exceptionally pure, cutting-edge plasmids. With the investment and support of ArchiMed, PlasmidFactory will shortly fund the construction of an even larger GMP (Good Manufacturing Practices) compliant facility.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account